What is the plasma quality ?
Plasma quality in vitro
Plasma quality is maintained after treatment:
- No influence on complement system, inhibitors of coagulation, fibrinolysis markers or ADAMTS13.
- Coagulation factors and activation are only moderately affected and remain within the specifications set by the Council of Europe Guidelines.
- Moderate enhanced thrombin time and aPTT.
- Very little effect on the strength of clot formation as assessed by thrombelastometry (Cardigan et al., Transfusion 2009).
MB plasma and TTP
Studies from a Spanish group* indicate inferiority of MB plasma compared to quarantine plasma but:
- The overall remission rates were not different- the study was not blinded for the plasma types.
- Mean patient number was 1 per hospital per year over a three year period.
- Diverse MB plasma types available in Spain (Grifols, MacoPharma) which were not differentiated.
Further studies are necessary.*del Rio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castella D, de la Rubia J, Zamora C, Corral M, Viejo A, Pena F, Rodriguez-Vicente P, Contreras E, Arbona C, Ramirez C, Garcia-Erce JA, Alegre A, Mateo J, Pereira A: Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143(1):39-45. _
Plasma parameters of whole blood-derived plasma after MB treatment with different methodsBibliography:
1/ Sondag-Thull D. Plasma unitaire viro-inactivé bleu de méthylène. 2004; Croix-Rouge de Belgique Service du Sang. Brussels.
2/ Castrillo A, Eiras A, Castro A, Adelantado M, Areal C, Cid J, Flores J, Solla E, Garcia-Villaescusa R. A new evaluation of methylene blue treated plasma. Transfus Clin Biol 2001; 8:103s.
3/ Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11:31-36.
4/ Verpoort T, Chollet S, Lebrun F, Goudaliez F, Mohr H, Walker WH. Elimination of Methylene Blue from photodynamically treated virus inactivated fresh frozen plasma: the Blueflex filter. Transfus Clin Biol 2001; 8:103s.
5/ Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, Williamson LM, Prowse CV The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003; 43:1238-1247.
6/ Reichenberg S, Walker WH, Hoburg A, Müller N. Theraflex MB-Plasma procedure: Plasma quality after 15 month storage and reduction of Methylene Blue and photoproducts. Vox Sang 2006; 91:P386.
7/ Gravemann U, Pohler P, Reichenberg S, Budde U, Walker WH, Mohr H, Müller TH. Quality and stability of methylene blue-treated plasma prepared under worst case conditions. Vox Sang 2005; 89:8-27.
8/ Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004; 14:39-44.
9/ Larrea L, Ortiz de Salazar MI, Martínez P, Roig R. Quantitative analysis of plasma proteins in whole blood derived fresh frozen plasma prepared with three pathogen reduction technologies. Tranfusion and Apheresis Science 2015; 52:305-310
10/ Aznar JA, Bonanad S, Montoro JM, Hurtado C, Cid AR, Soler MA, de Miguel A. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000; 79:156-160.
11/ Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible Light. Vox Sang 1991; 60:207-213.
12/ Mohr H, Knuver-Hopf J, Lambrecht B, Scheidecker H, Schmitt H. No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol 1992; 65:224-228.
13/ Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Muller C, Heuft HG, Huhn D. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994; 34:685-689.
14/ Aznar JA, Molina R, Montoro JM. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 1999; 39:748-750.
15/ Riggert J, Humpe A, Legler TJ, Wolf C, Simson G, Kohler M. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion 2001; 41:82-86.
16/ Seghatchian J, Krailadsiri P. What’s happening? The quality of methylene blue treated FFP and cryo. Transfus Apher Sci 2001; 25:227-231.
17/ Cardigan R, Allford S, Williamson L. Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 2002; 117:253-254.